Loading clinical trials...

Probing the Cannabinoid System in Individuals With a Family History of Psychosis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGEARLY_PHASE1

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

NCT02102113•Yale University

Summary

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Exposure to cannabis at least once in their lifetime
•Medically and psychiatrically healthy based on screening
•Having one relative with a confirmed psychotic disorder
•Exposure to cannabis at least once in their lifetime
•Medically and psychiatrically healthy based on screening

Exclusion Criteria

•Current or lifetime major DSM-IV Axis I disorder
•Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness
•Major or unstable medical illness that might impact safety of the subject in the study
•Cannabis naive
•IQ less than 85
•Less than a high school diploma or its educational equivalent
•Pregnancy or lactation
•Major current or recent (\<6 weeks) psychosocial stressors.
•Having a family member with psychosis
•Current or lifetime major DSM-IV Axis I disorder
+7 more criteria

Locations (1)

VA Connecticut Healthcare System

West Haven, Connecticut, United States

Key Dates

Start Date

January 1, 2014

Primary Completion Date

June 1, 2026

Completion Date

December 1, 2026

Last Updated

June 10, 2025

Enrollment

ESTIMATED participants

Conditions

PsychosisCannabis UseTHCMarijuanaSchizophrenia

Interventions

Placebo

DRUG

Very Low Dose THC

DRUG

Low Dose THC

DRUG

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGPHASE1/PHASE2

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

NCT07226895

Clinical High Risk for Psychosis (CHR)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

ACP-204 in Adults With Alzheimer's Disease Psychosis

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use